These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38958419)

  • 1. How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?
    Dong KA; Duthie KM
    AMA J Ethics; 2024 Jul; 26(7):E512-519. PubMed ID: 38958419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
    Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
    Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
    Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
    Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overdose prevention: naloxone with long acting opioids.
    Bowman S; McKenzie M; Rich J
    Med Health R I; 2008 Sep; 91(9):271-2. PubMed ID: 18834043
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review.
    Englander H; Thakrar AP; Bagley SM; Rolley T; Dong K; Hyshka E
    JAMA Intern Med; 2024 Jun; 184(6):691-701. PubMed ID: 38683591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment.
    Raheemullah A; Lembke A
    JAMA Intern Med; 2019 Mar; 179(3):427-428. PubMed ID: 30640372
    [No Abstract]   [Full Text] [Related]  

  • 13. Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL/6J mice.
    Bedard ML; Lord JS; Perez PJ; Bravo IM; Teklezghi AT; Tarantino LM; Diering GH; McElligott ZA
    Behav Brain Res; 2023 Jun; 448():114441. PubMed ID: 37075956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The attractiveness of opposites: agonists and antagonists.
    O'Brien T
    J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):67-9. PubMed ID: 25643224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
    Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
    J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
    Skains RM; Reynolds L; Carlisle N; Heath S; Covington W; Hornbuckle K; Walter L
    West J Emerg Med; 2023 Nov; 24(6):1010-1017. PubMed ID: 38165181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced analgesia with opioid antagonist administration.
    Loitman JE
    J Palliat Med; 2006 Dec; 9(6):1250-3. PubMed ID: 17187530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
    Lofwall MR; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.